1型糖尿病中的-葡萄糖共运输体-2抑制剂:关于其潜在使用的建议框架
Djordje S Popovic1, Dimitrios Patoulias2, Theocharis Koufakis2
1Medical Faculty, Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, University of Novi Sad, Novi Sad, Serbia.
概括
-葡萄糖共载体-2抑制剂 (SGLT2is) 对1型糖尿病 (T1D) 管理提供了适度的益处,包括改善血糖控制和降低心血管风险. 然而,由于糖尿病酸症 (DKA) 的风险增加,仔细选择患者至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 1型糖尿病 (T1D) 与肥胖,血糖控制和心血管并发症存在挑战.
- 目前对T1D的治疗方法往往无法解决这些多方面的问题.
- 目前正在探索非胰岛素降血糖剂来增强T1D治疗.
研究的目的:
- 评估-葡萄糖共载体-2抑制剂 (SGLT2is) 在1型糖尿病 (T1D) 中的潜在益处.
- 讨论SGLT2在其他疾病中观察到的心脏脏保护作用.
- 提出SGLT2is在T1D中安全有效使用的框架.
主要方法:
- 对T1D中SGLT2is的可用随机对照试验证据的审查.
- 对SGLT2的分析是独立于胰岛素分泌的降糖机制.
- 评估与SGLT2is相关的心脏益和风险.
主要成果:
- 作为T1D的辅助疗法,SGLT2显示HbA1c和体重的适度降低.
- 在SGLT2的研究中,已经显示出白蛋白尿的改善,可能会延迟慢性病 (CKD) 的进展.
- 糖尿病酸症 (DKA) 的风险显著增加与SGLT2在T1D中的使用有关.
结论:
- SGLT2is可能为T1D提供有价值的辅助疗法,改善代谢和心结局.
- 在在T1D患者中开始SGLT2is之前,糖尿病酸症 (DKA) 的风险分层是必不可少的.
- 个人化治疗策略考虑血糖控制,心状况和DKA风险,建议SGLT2is在T1D.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
163
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
163
Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173


